Citations

Clear

313 citation(s) found for "Alvarez, P".

Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia
Cabrera-Serrano, Antonio José , Rodríguez‐Sevilla, Juan José , Reyes‐Zurita, Fernando J. , Collado, Rosa , Puiggros, Anna, Cornejo-Calvo, Elena , Horst, Rob ter , Benavente, Yolanda , Jerez, Andrés , Ramos‐Campoy, Sílvia , González‐Olmedo, Carmen , Jannus, Fatin , Marcos‐Gragera, Rafael , Carretero-Fernández, María, Sampaio‐Marques, Belém , Gámez, Irene, García‐Álvarez, María , Camp, Nicola J. , Kamaso, Joanna, Pérez, Eva María, Alcoceba, Miguel , Campa, Daniele , Sanjosé, Sílvia de , Netea, Mihai G. , McKay, James, Casabonne, Delphine , Berndt, Sonja I. , Sáinz, Juan , Rodríguez-Sevilla, Juan José , Reyes-Zurita, Fernando Jesús , Collado, Rosa , Cornejo-Calvo, Elena , Ter Horst, Rob , Landi, Stefano , Espinet, Blanca , Maffei, Rossana , López-Nevot, Miguel Ángel , Ramos-Campoy, Silvia , Chen-Liang, Tzu-Hua , Jannus, Fatin , Marcos-Gragera, Rafael , Carretero-Fernández, María , Sampaio-Marques, Belém , Camp, Nicola J , Dierssen-Sotos, Trinidad , Kamaso, Joanna , Li, Yang , Marasca, Roberto , Ludovico, Paula , Canzian, Federico , Casabonne, Delphine , Berndt, Sonja I , Slager, Susan L , Sainz, Juan , Alcoceba, Miguel , Sánchez‐Maldonado, José Manuel , Puiggros, Anna , García-Martín, Paloma, Landi, Stefano , Espinet, Blanca , Maffei, Rossana , López‐Nevot, Miguel Ángel , Moreno, Vı́ctor , Dierssen‐Sotos, Trinidad , Norman, Aaron D. , Luppi, Mario , Li, Yang , Marasca, Roberto , Ludovico, Paula , Clay‐Gilmour, Alyssa , Canzian, Federico , Ibáñez, Mariam , McKay, James , Slager, Susan L. , Netea, M. G.

Mayo Clinic

Blood Advances | September 3, 2025 | Volume: 9 | Issue: 23 | Pages: 6076-6089

10.1182/bloodadvances.2025017345 | PMID 40902075 Get It

Abstract We investigated the influence of 55 583 autophagy-related single-nucleotide polymorphisms (SNPs) on chronic lymphocytic leukemia (CLL) risk across 4 independent populations comprising 5472 CLL cases and 726 465 controls. We also examined their impact on overall survival (OS), time to first treatment (TTFT), autophagy flux, and immune responses. A meta-analysis of the 4 populations identified, to our knowledge, for the first time, significant associations between CDKN2A (rs3731204) and BCL2 (rs4940571, rs12457371, and rs1026825) SNPs and CLL risk, with CDKN2A showing the strongest association (P = 1.57 × 10−12). We also validated previously reported associations for FAS, BCL2, and BAK1 SNPs with CLL risk (P = 4.73 × 10−21 to 3.39 × 10−9). The CDKN2Ars3731204 and FASrs1926194 SNPs associated with increased CDKN2A and ACTA2 messenger RNA expression levels in the whole blood and/or lymphocytes (P = 5.1 × 10−7, P = 1.58 × 10−21, and P = 7.8 × 10−41), although no significant effect on autophagy flux was observed. However, associations were found between CDKN2A, BCL2, and FAS SNPs and various T-cell subsets, cytokine production, and circulating concentrations of interferon gamma, tumor necrosis factor–related apoptosis-inducing ligand, CD40, chemokine ligand 20, and interleukin-2 receptor subunit β proteins (P ≤ .005). No significant association was detected between autophagy variants and OS or TTFT, suggesting that these variants drive disease initiation rather than progression. In conclusion, this study identified 4 novel associations for CLL and provided insights into the biological pathways that influence CLL development.
Outcome Evaluation of Volume-Staged Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations
Mantziaris, Georgios , Hajikarimloo, Bardia , Tos, Salem M , Pikis, Stylianos , Chan, Jason W., Sneed, Penny K. , McDermott, Michael W. , Seymour, Zachary , Grills, Inga S., Reda, Wael A. , Tawadros, Sameh R. , Emad, Reem M. , Lunsford, L. Dade , Niranjan, Ajay , Lee, Cheng‐Chia , Sheehan, Darrah, Sheehan, Kimball , Chytka, Tomáš , Meng, Ying , Moreno, Nuria Martínez , Álvarez, Roberto Martínez , Hallan, David R , Fritch, Chanju , Jareczek, Frank, Sciscent, Bao Y. , Carrier, Louis, Abdelsalam, Ahmed Ragab , Starke, Robert M. , Benjamin, Carolina , Singh, S.P., Lazo, Erwin , Esquenazi, Yoshua , Blanco, Angel I., Picozzi, Piero, Lanterna, Luigi Alberto Andrea, Bowden, Greg , Peterson, Jennifer , Chiang, Veronica , Ishaque, Mariam , Sheehan, Jason P. , Bin-Alamer, Othman , Mantziaris, Georgios , Nabeel, Ahmed M. , Reda, Wael A. , Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Bin-Alamer, Othman , Peker, Selçuk , Samancı, Yavuz , Yang, Huai‐Che , Liščák, Roman , Alzate, Juan Diego , Kondziolka, Douglas , Jareczek, Frank, Mathieu, David , Carrier, Louis, Almeida, Timóteo , Tripathi, Manjul , Speckter, Herwin , Chen, Ching‐Jen , Becerril‐Gaitan, Andrea , Amsbaugh, Mark J. , Upadhyay, Rituraj , Palmer, Joshua D. , Franzini, Andrea , Picozzi, Piero , Warnick, Ronald E. , Protopapa, Maria

Mayo Clinic

Neurosurgery | August 11, 2025 | Volume: 98 | Issue: 1 | Pages: 174-184

10.1227/neu.0000000000003682 | PMID 40788018 Get It

BACKGROUND AND OBJECTIVES: Single-session stereotactic radiosurgery (SRS) has limited role for large arteriovenous malformations (AVM). Volume-staged SRS (VS-SRS) is used to optimize outcomes, but studies reporting results are limited. METHODS: This multicenter retrospective cohort of 378 patients from 21 centers reports results of VS-SRS for the entire AVM nidus. We report favorable outcome, obliteration, hemorrhage, and permanent symptomatic adverse radiation effect rates. RESULTS: The median age was 31 years (IQR: 19-44) at the first volume stage, with patients treated in 2–4 stages. The median total nidus volume was 21 cm 3 (IQR: 13.9-30.1 cm 3 ), and a median prescription dose of 17 Gy (IQR: 16-18 Gy) was used. The median radiographic and clinical follow-up were 48 and 55 months, respectively. Seventy-seven patients (20.4%) had a favorable outcome, with the 3-year and 5-year rates being 3.9% and 18%, respectively. 127 patients (33.6%) achieved obliteration, with the 3-year and 5-year rates being 6.8% and 26%, respectively. Obliteration rates of AVMs <15 cm 3 were 81% and 31%, respectively. The latency period hemorrhage incidence rate was 3.02 cases per 100 patient-years; 52 patients (13.8%) had a bleed. Seventy-two patients (19%) had symptomatic adverse radiation effect; in 38 patients (10.1%), these were permanent. Total nidus volume, prescription dose at first stage, diffuse nidus, and prior hemorrhage were all independent affecting outcome rates. CONCLUSION: VS-SRS can be used to treat large AVMs as a standalone treatment. Obliteration rates and favorable outcomes are lower than that with smaller AVMs, and repeat treatment is often required. Optimizing treatment plans, by increasing prescription doses, reducing treatment volume at each stage, and increasing the number of stages, may lead to better outcomes.
Single-cell multiomics identifies both shared and unique features of immune dysfunction in Parkinson’s disease and inflammatory bowel disease colon, plasma and stool
Buendia, Marc, Shi, Ji , Kachergus, Jennifer M., Efron, Philip A. , Alvarez, Stephan D. , Xue, Qing‐Shan, Zimmermann, Ellen M. , Forsmark, Christopher E. , Thompson, E. Aubrey, Bolen, MacKenzie L. , Buendia, Marc, Staley, Hannah A. , Park, Gwoncheol , Nagpal, Ravinder , McFarland, Nikolaus R. , Menees, Kelly B , Salas, Azucena , Thompson, E. Aubrey, Tansey, Malú G.

Mayo Clinic

No container title available | July 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7115293/v1 Get It

Abstract Parkinson’s disease (PD) is the fastest growing neurodegenerative disease in the world1. Gastrointestinal (GI) dysfunction can occur decades before motor impairments and in up to 80% of individuals living with PD2,3,4. We investigated peripheral relationships that may underlie environmental contributions to mechanisms along the gut-blood axis that contribute to PD pathogenesis. Single-cell multiomic spatial molecular imaging (SMI) of colonic tissue localized inflammatory injury within epithelial cells that appear to be associated with iron mishandling in both inflammatory bowel disease (IBD) and PD biosamples. We found that both the single-cell SMI of RNA and protein revealed parallel cross-modal dysregulation in the gut epithelium, in both IBD and PD biosamples. These data are accompanied by plasma (PD) and stool (IBD) protein depletion of CCL22. Our findings suggest iron mishandling along the gut barrier likely contributes to systemic inflammation, which may be the catalyst that primes circulating immune cells to body-first PD pathogenesis.
Vulvar Dermatofibrosarcoma Protuberans: Surgical Planning and Management Considerations for the Dermatologic Surgeon
Lachman, Nirusha , Salinas‐Alvarez, Yolanda , Demer, Addison M. , Vidal, Nahid Y. , Reinhart, Jacob P. , Salinas-Alvarez, Yolanda, Salinas-Alvarez, Yolanda

Mayo Clinic

Dermatologic Surgery | July 18, 2025 | Volume: 52 | Issue: 1 | Pages: 24-30

10.1097/dss.0000000000004739 | PMID 40680296 Get It

Background Dermatofibrosarcoma protuberans (DFSP) arising in the vulvar and perivulvar region poses unique challenges to the dermatologic surgeon. The potential for broad subclinical extension and involvement of deeper and high-risk functional structures requires a strong knowledge of relevant anatomy. Careful considerations are required for preoperative arrangements, surgical day preparations, and postoperative surveillance to improve treatment outcomes and patient experiences. Objective The authors aim to provide a practical guide for the dermatologic surgeon, which outlines surgical planning and management recommendations for vulvar DFSP. Emphasis on pelvic anatomy through cadaveric and patient images as well as anatomical illustrations will be included. Materials and Methods A literature review was performed to identify evidence-based management recommendations for vulvar DFSP. Authors share anecdotal perioperative recommendations for optimizing the patient experience. A detailed pelvic dissection of a female cadaver was performed for anatomical depiction of relevant high-risk structures. Illustrations of sensory nerve distributions were created for reference. Conclusion Vulvar DFSP is a challenging cutaneous tumor in a sensitive anatomical location. As Mohs surgery offers clear advantages over wide local excision, the authors provide dermatologic surgeons with detailed anatomy review resources as well as recommendations and considerations for management and perioperative planning for this specialized site.
Roadblocks of Urinary EV Biomarkers: Moving Toward the Clinic
Droste, Marvin , Puhka, Maija , Ng, Monica Suet Ying , Álvarez‐Llamas, Gloria , Borràs, Francesc E. , Büscher, Anja , Bussolati, Benedetta , Dear, James W. , Hoorn, Ewout J. , Lenassi, Metka , Pink, Desmond , Tiwari, Swasti , Vizio, Dolores Di , Zarovni, Nataša , Martens‐Uzunova, Elena S. , Erdbrügger, Uta , Ng, Monica S Y , Alvarez-Llamas, Gloria , Borràs, Francesc E , Bussolati, Benedetta , Falcón-Perez, Juan Manual , Lenassi, Metka , Lucien, Fabrice , Tertel, Tobias , Martens-Uzunova, Elena S , Royen, Martin E. van , Blijdorp, Charles J. , Falcón‐Pérez, Juan Manuel , Giebel, Bernd , Grange, Cristina , Leivo, Janne , Llorente, Alicia , Lucien, Fabrice , Mertens, Inge , Mischak, Harald , Yuen, Peter S.T. , Jenster, Guido , Burger, Dylan

Mayo Clinic

Journal of Extracellular Vesicles | July 17, 2025 | Volume: 14 | Issue: 7 | Pages: No page available

10.1002/jev2.70120 | PMID 40673839 Get It

ABSTRACT Despite remarkable interest in the biomarker potential of urinary extracellular vesicles (uEVs) and the identification of numerous promising candidates, their clinical translation still presents multiple challenges. The opportunities for successful translation are obvious, yet the main roadblocks on the way have hardly been systematically considered and more coordinated approaches are needed to overcome them. In the present review article, we have identified the most relevant roadblocks of clinical translation of urinary EV‐based biomarkers and discuss possible solutions to overcome them. These roadblocks are categorized as fundamental and technical but also related to development of novel biomarker assays and clinical acceptance. In addition, hurdles within the regulatory approval process are discussed. It is clear that various roadblocks to clinical translation of urinary EV biomarkers exist; however, they are addressable by promoting rigor and reproducibility as well as collaboration between basic and clinical scientists, clinicians, industry and regulatory bodies. Moreover, knowledge of obstacles for assay development and regulatory requirements should already be considered when developing a new biomarker to maximize the chance of successful translation. This review presents not only a status quo, but also a roadmap for the further development of the field.
Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital
Mulett, Sergio Alvarez , Garcia, Sofia Molina , Saleh, Omar Abu , Rodning, Amanda A, Wengenack, Nancy L. , Patel, Robin , Alvarez Mulett, Sergio , Molina Garcia, Sofia , Abu Saleh, Omar , Wolf, Matthew J, Wengenack, Nancy L , Patel, Robin , Wolf, Matthew J, Norgan, Andrew P.

Mayo Clinic

Clinical Infectious Diseases | July 16, 2025 | Volume: 82 | Issue: 5 | Pages: 808-814

10.1093/cid/ciaf390 | PMID 40668900 Get It

Abstract Background Central nervous system (CNS) infections are significant causes of morbidity and mortality, especially when diagnosis is delayed. Traditional cerebrospinal fluid diagnostic methods for CNS infections have limited sensitivity. Metagenomic next-generation sequencing of cerebrospinal fluid (MSCSF) is a newer diagnostic tool capable of detecting a broad range of pathogens in a single assay. Methods This retrospective cohort study evaluated the first-year experience with MSCSF at Mayo Clinic. A total of 422 tests performed during calendar year 2024 on adult patients at Mayo Clinic facilities and those tested through Mayo Clinic Laboratories were analyzed, with a subcohort analysis of the 210 Mayo Clinic patients performed to define patient characteristics associated with positive results and clinical outcomes. Results The sensitivity of MSCSF for detecting neuroinfection in the subcohort was 64%, with 43% of confirmed neuroinfections diagnosed by MSCSF only. Subjects who were immunosuppressed (odds ratio [OR]: 3.5, P = .008) and those with a high pretest probability of CNS infection (OR: 20.1, P &lt; .001) were more likely to have positive results. Also, those who tested positive were more likely to die within the ensuing 30 days than those who tested negative (OR: 5.2, P = .001). Conclusions MSCSF can be a valuable tool for diagnosing CNS infection but should not be used indiscriminately. It appears to be most beneficial when there is a high clinical suspicion of CNS infection and conventional diagnostics, and available molecular tests, yield negative results. Its integration into clinical practice should be guided by diagnostic stewardship to maximize cost-effectiveness and clinical utility.
Brain atrophy patterns in anti-IgLON5 disease
Yogeshwar, Selina , Bartels, Frederik , Muñiz‐Castrillo, Sergio , Picard, Géraldine , Bernard, E , Ζεκερίδου, Αναστασία , Ringelstein, Marius , Kraft, Andrea , Kovac, Stjepana , Wandinger, Klaus‐Peter , Vries, Juna M. de, Boon, Agnita J.W. , Veenbergen, Sharon , Penner, Loana , Gaig, Carles , Sabater, Lídia , Santamaría, Joan , Prüß, Harald , Lewerenz, Jan , Irani, Sarosh R. , Mignot, Emmanuel , Titulaer, Maarten J. , Ayzenberg, Ilya , Francillard, Aurélie Méneret Isabelle, Renard, Dimitri , Desestret, Virginie, Capet, Nicolas , Davion, Jean‐Baptiste , Boucher, Julie, Combres, Helene, Rafiq, Marie , Bonneville, Fabrice , Cumin, Marina, Soulages, Antoine , Compoint, Mathilde, Moulin, Maximilien , Berling, Édouard , Garrigues, Eve, Chanson, Marine, Bourg, Veronique , Giordana, Caroline, Benoit, Jeanne , Flabeau, Olivier, Derivoyre, Emmanuelle, Ryckewaert, Gilles, Alberto, Tifanie, Carrière, Nicolas , Mostoufizadehs, Sohrab, Barbay, Mélanie , Bénaiteau, Marie , Sellal, François , Casez, Olivier, Bruel, Cédric , Kalifa, L G, Rusu, Elena Camelia, Demortière, Sarah , Maarouf, Adil, Wang, Adrien , Brasset, Adelaide, Attal, Arthur, Demourant, Céline, Houéto, Jean‐Luc , Brueggemann, Norbert, Dargvainiene, Justina , Oy, Ulrich Hofstadt‐van , Nagel, Michael , Urbanek, Christian, Schroeder, Ina, Schramm, Peter , Tonner, Silke, Seitz, Caspar , Tschernatsch, Marlene , Chung, Ha‐Yeun , Wickel, Jonathan , Schoeberl, Florian, Macher, Stefan , Simabukuro, Mateus Mistieri , Zittel-Dirks, Simone, Wildemann, Brigitte , Kothaj, Ján, Ordás, Carlos , Angstwurm, Klemens , Tomás, Ángela Milán, Bastida, Antonio Martin, Quintas, Sonia , Kimura, Akio , Akira, Takekoshi, Scheller-Nissen, Mette, Hartmann, Christian, Bastiaansen, Danielle, Steenhoven, Robin van, Schwichtenberg, Katia , Yogeshwar, Selina M , Grüter, Thomas , Muñiz-Castrillo, Sergio , Melzer, Nico , Leypoldt, Frank , Pittock, S J , Höftberger, Romana , Howe, Charles L , Irani, Sarosh R , Mignot, Emmanuel , Honnorat, Jérôme , Finke, Carsten , Titulaer, Maarten J , Crijnen, Y S , Heidbreder, Anna , Geis, Christian , Blaabjerg, Morten , Pittock, Sean J. , Graus, Francesc , Dalmau, Josep , Schreiner, Bettina , Honnorat, Jérôme , Méneret, Aurélie , Desestret, Virginie , Boucher, Julie, Zéphir, Hélène , Damier, Philippe , Combres, Hélène, Cumin, Marina, Compoint, Mathilde, Chanson, Marine, Vogrig, Alberto , Casez, Olivier , Kalifa, Laurette, Rusu, Elena Camelia, Carra‐Dallière, Clarisse , Cluse, Florent , Brueggemann, Norbert, Seifert‐Held, Thomas , Villacieros‐Álvarez, Javier , Berger–Sieczkowski, Evelyn , Tambasco, Nicola , Nigro, Pasquale , Iorio, Raffaele , Ono, Yoya , Shimohata, Takayoshi , Bastiaansen, Danielle

Mayo Clinic

Brain | July 12, 2025 | Volume: 149 | Issue: 3 | Pages: 884-896

10.1093/brain/awaf256 | PMID 40650880 Get It

Abstract Anti-IgLON5 disease is an autoimmune encephalitis that presents with a heterogenous clinical phenotype, including sleep disorders, movement abnormalities and bulbar involvement. It is characterized by autoantibodies against IgLON5, 85% association with HLA-DQB1*05:∼ and a brainstem-dominant tauopathy. Cellular and murine models report pathogenic effects of the autoantibodies, and neurodegenerative factors suggest progressive atrophy as a common sequela. However, evidence from in vivo patient data and long-term follow-up is limited, and the degree of progression remains elusive. In this multicentre study, clinical and brain MRI data were collected from 127 patients across 12 countries to investigate the relationships between clinical presentations and the development of distinct brain atrophy patterns. Our data show that most patients develop a complex multisystem phenotype as the disease progresses; however, neuromuscular manifestations rarely emerge at later disease stages. By comparison to healthy controls, this disease presents with severe substructure-specific atrophy, especially affecting the hypothalamus, brainstem, accumbens and basal ganglia, which, in age-independent analyses, show significant ventricular enlargement and also suggest progression of brainstem atrophy over the disease course. Moreover, the focality of atrophy was functionally linked to specific symptoms, with more severe involvement of the basal ganglia in patients with movement disorders, and greater atrophy in the hippocampus and thalamus in patients with cognitive impairment. Taken together, our results provide evidence of distinct atrophy patterns in anti-IgLON5 disease, which closely mirror sites of pathophysiologic processes, including autoantibody binding and tau deposition. Our data emphasize the brainstem as the pathophysiological hub of the disease and provide normative data for the incorporation of atrophy measurements into routine clinical assessments and future treatment studies to monitor disease trajectory and evaluate future treatment strategies.
Sacral fracture risk after stereotactic spinal radiosurgery: a multi-institution, retrospective analysis
Goethe, Eric A. , Almeida, Romulo Augusto Andrade de, Mikula, Anthony L. , Merrell, Kenneth W. , Rose, Peter S. , Karim, S. Mohammed, Linzey, Joseph R. , Szerlip, Nicholas J. , Ghia, Amol J. , Li, Jing , McAleer, Mary Frances, Perni, Subha , Yeboa, D.N. , Rhines, Laurence D. , North, Robert Y. , Almeida, Rômulo Augusto Andrade de , Call-Orellana, Francisco Alfredo , Clarke, Michelle J. , Amini, Behrang , Beckham, Thomas Hendrix , Tom, Martin C. , McAleer, Mary Frances , Wang, Chenyang , Price, Anthony, Alvarez‐Breckenridge, Christopher , Tatsui, Claudio Esteves

Mayo Clinic

Journal of Neurosurgery: Spine | June 20, 2025 | Volume: 43 | Issue: 3 | Pages: 305-312

10.3171/2025.2.spine24770 | PMID 40540799 Get It

OBJECTIVE Spinal stereotactic radiosurgery (SSRS) is an established treatment modality for spinal metastatic disease. A common complication of SSRS is postradiation pathologic fracture. The authors evaluated the risk of pathologic fracture in sacral SSRS. METHODS All patients receiving SSRS in 1 to 5 fractions to 1 or more sacral levels between 2011 and 2020 at participating institutions were included. Demographic, histological, anatomical, and outcome data were obtained from electronic medical records. Data were analyzed using SPSS version 28. RESULTS Of 67 total patients, 50 (74.6%) were men and 17 (25.4%) were women. The most common tumor histologies were prostate adenocarcinoma (n = 16 [23.9%]) and renal cell carcinoma (n = 12 [17.9%]). Median (range) age at treatment was 63 (8–87) years. The mean ± SD (range) number of levels treated was 1.5 ± 0.7 (1–4) levels. Mean ± SD (range) bone density at S1 was 208.0 ± 74.4 (−3.0 to 443.3) Hounsfield units (HUs). Median (range) follow-up was 16.6 (1.5–132) months, median ± SD (range) overall survival was 24 ± 21.0 (1.7–83.3) months, and the 1-year local control rate was 83.6%. Fourteen patients (20.9%) experienced fracture within the radiation field. There was no association between fracture and patient sex (p = 0.32), age (p = 0.40), S1 HU (p = 0.28), tumor location according to Denis classification (p = 0.87), presence of pain (p = 0.66), single versus multifraction radiation (p = 0.44), or number of levels treated (p = 0.52). Patients experiencing in-field progression were more likely to experience fracture (61.5% vs 10.2%, p < 0.001), and patients experiencing fracture had a higher average Spine Instability Neoplastic Score than patients without fracture (5.7 vs 4.3, p = 0.049). Only local control remained as a factor associated with sacral fracture in the multivariate analysis. Of the patients experiencing fracture, 10 (71.4%) were symptomatic and 3 of those (30.0%) underwent post-SSRS surgical intervention. CONCLUSIONS Pathologic fracture may occur after sacral SSRS in a significant number of patients and is significantly associated with failure of local control.
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.
Vannucchi, Alessandro M. , Mascarenhas, John , Bose, Prithviraj , Gale, Robert Peter , Harrison, Claire , Hehlmann, Rüdiger , Koschmieder, Steffen , Tefferi, Ayalew , Barbui, Tiziano , Vannucchi, Alessandro M , Mascarenhas, John , Gale, Robert P , Bose, Prithviraj , Koschmieder, Steffen , Marchetti, Monia , Álvarez‐Larrán, Alberto , Hehlmann, Rűdiger, Kiladjian, Jean‐Jacques , Mesa, Ruben A. , Passamonti, Francesco , Rambaldi, Alessandro

Mayo Clinic

No container title available | June 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6785954/v1 Get It

Abstract Most myelofibrosis (MF) drug approvals by Health Authorities are based on 1 or 2 outcome measures such as spleen volume reduction and/or improved quality-of-life. This 1–2 dimensional approach fails to capture the clinical complexity of MF. A European LeukemiaNet (ELN) taskforce developed a composite endpoint which allows multiple outcomes to be simultaneously measured. The panel used the Desirability-Of-Outcome-Ranking (DOOR) method to assign 25 outcomes into 4 quartiles based on a multi-dimensional desirability score and build a 5-layer composite outcome named Desirability-of-Myelofibrosis-Outcomes (DEMYO). Outcome operational definitions were tested by Delphi consensus and correlations with survival validated by a literature review. The outcomes assigned to the first two quartiles were negatively correlated with leukemia-free survival and survival. DEMYO comprehensively captures relevant MF clinical features and meaningful endpoints. Despite DEMYO requires validation based on available trial data, it is expected to improve the quality of Health Authority approvals for new drugs for MF.
CD39 REGULATES P2RX7-MEDIATED LUNG NECROTIC LESIONS IN SEVERE EXPERIMENTAL TUBERCULOSIS
Santos, Gislane de Almeida , Santiago-Carvalho, Igor , Almeida, Fabrício Moreira, Bomfim, Caio César Barbosa , Silva, Juan Carlo Santos e , Cantarini, D. , Silva, Camila Ramos , Raeder, Paulo Henrique Lisboa, Teixeira-Xavier, Joaquim , Álvarez, José María , de Almeida Santos, Gislane , Ribeiro, Martha Simões , Nascimento, Rogério Silva do , Macedo, Bruna de Gois , Raeder, Paulo Lisboa , Hirata, Mário Hiroyuki , Coutinho‐Silva, Robson , Robson, Simon Christopher , Amaral, Eduardo P. , Lasunskaia, Elena , Lima, Maria Regina D’Império

Mayo Clinic

No container title available | May 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.28.656614 Get It

SUMMARY Tuberculosis induces diverse lesions, such as necrotic pneumonia, contributing to disease progression and transmission. Despite advances in understanding the role of ATP-gated P2RX7 ion channels in developing severe forms of tuberculosis, the regulation of this important signaling pathway remains unclear. Herein, we show that the ectonucleotidase CD39 plays an essential regulatory role in TB progression by preventing lung tissue damage, bacterial dissemination, and excessive inflammatory responses. Mechanistically, through its enzymatic activity on the cellular surface, CD39 protects infected macrophages from undergoing necrotic death mediated by P2RX7 activation. We proposed that by protecting macrophages from P2RX7-mediated cell death and bacterial dissemination, CD39 prevents the development of necrotic lesions. Altogether, these findings uncover a significant role for CD39 as an essential component of the molecular regulation underlying the development of severe tuberculosis. GRAPHICAL ABSTRACT Brief In tuberculosis, necrotic granuloma-like structures release extracellular ATP (eATP), which triggers P2RX7-mediated immune cell death. CD39 degrades eATP, preventing P2RX7 activation and promoting macrophage survival, thereby limiting inflammation, tissue damage, and bacterial dissemination.